Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24876166 | 0.80 | CA14 (0.39) | CA14CACNA1GCACNA1BCACNA1CPDK2 | |
| SCHEMBL21106384 | 0.79 | CA14 (0.31) | CA14CACNA1GCACNA1BCACNA1C | |
| SCHEMBL25363450 | 0.76 | CA14 (0.38) | CA14CACNA1GCACNA1BCACNA1CPDK2 | |
| SCHEMBL14443433 | 0.75 | HDAC6 (0.38) | CA14CACNA1GCACNA1BCACNA1CPDK2 | |
| SCHEMBL31122416 | 0.74 | CTSK (0.45) | CA14CACNA1GCACNA1BCACNA1CPDK2 | |
| SCHEMBL21804725 | 0.74 | HDAC6 (0.41) | CA14CACNA1GCACNA1BCACNA1CPDK2 | |
| SCHEMBL20934891 | 0.72 | CA14 (0.35) | CA14CACNA1GCACNA1BCACNA1CPDK2 | |
| SCHEMBL25901934 | 0.72 | CA14 (0.35) | CA14CACNA1GCACNA1BCACNA1CPDK2 | |
| SCHEMBL25901849 | 0.72 | CA14 (0.35) | CA14CACNA1GCACNA1BCACNA1CPDK2 | |
| SCHEMBL15584545 | 0.72 | HDAC6 (0.38) | CA14CACNA1GCACNA1BCACNA1CPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CA14 4601/4885CACNA1G 4810/4885CACNA1B 4740/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CA14 4601/4885CACNA1G 4810/4885CACNA1B 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.